替吉奥联合奈达铂二线治疗晚期非小细胞肺癌的疗效观察

Clinical effects of combination therapy of Nedaplatin and S-1 for advanced non-small-cell lung cancer

目的观察替吉奥联合奈达铂对一线治疗后晚期非小细胞肺癌患者的有效性和安全性。方法确定一线治疗进展的37例晚期非小细胞肺癌患者二线接受替吉奥联合奈达铂化疗。结果化疗客观有效率(CR+PR)为24.32%,疾病控制率(CR+PR+SD)为59.46%。1年生存率为56.8%,中位无进展生存时间为11.2个月(95%CI,8.697-13.703)。治疗后常见的毒副作用为Ⅰ-Ⅱ度骨髓抑制,皮肤色素沉着,无明显胃肠道反应,严重的骨髓抑制发生率低。结论替吉奥联合奈达铂治疗晚期非小细胞肺癌的有较好的疗效,毒副作用较轻,患者耐受性良好,可改善患者的生存质量,延长生存时间,为晚期非小细胞肺癌患者提供一种新的选择。

Objective To evaluate the efficacy and toxicity of treatment with Nedaplatin plus S-1 in patients with advanced non-small-cell lung cancer（NSCLC）. Methods A total of 37 cases accepted second-line chemotherapy with S-1 plus Nedaplatin.Results The remission rate（CR＋PR） was 24.32%,and the disease control rate（CR＋PR＋SD） was 59.46%. The 1-year survival rate was 56.8% and median PFS was 11.2 months（95%CI,8.697-13.703））. The major toxicities were I-II myelosuppression and skin pigmentation,and less gastrointestinal toxicity and myelosuppression were found in this study. Conclusion This chemotherapy regimen with Nedaplatin plus S-1 is a promising treatment for advanced NSCLC because of its high response rates,good survival rates,and mild toxicities.